Financial Performance - The company recorded revenue of approximately HKD 209.6 million for the year ended December 31, 2021, representing a 14.04% increase from HKD 183.8 million in 2020[5] - The net profit attributable to shareholders was HKD 2.4 million, a significant recovery from a loss of HKD 39.7 million in the previous year[5] - The group's revenue for the year reached approximately HKD 209.6 million, an increase of 14.04% compared to HKD 183.8 million in the previous year[20] - The net profit attributable to shareholders was approximately HKD 2.4 million, with basic earnings per share of HKD 0.05, a recovery from a loss of HKD 39.7 million and basic loss per share of HKD 0.79 in the previous year[20] - The company's gross profit for the year was HKD 97.4 million, an increase of approximately HKD 7.4 million from the previous year, with a gross margin of 46.5%[41] Business Expansion and Acquisitions - The company acquired 100% of Basic Dental, which owns the BIOTANIUM dental implant brand, enhancing its product offerings in the dental sector[7] - The group acquired 100% of Basic Dental Implant System, Inc., entering the high-value dental implant market, which has significant growth potential[24] - The company anticipates that the Shili Lianjiang project will contribute approximately RMB 250 million in contract sales starting in 2022[12] - The company plans to expand its rehabilitation services in Shenzhen and potentially extend these services to other core cities in the Greater Bay Area[14] - The company aims to enhance its dental business by expanding its sales network domestically and internationally, particularly in the U.S.[11] Research and Development - Research and development expenditure decreased to HKD 17.2 million from HKD 20.4 million, reflecting the management's commitment to investing in future technologies[24] - The company plans to establish a new high-tech enterprise focused on implant technology development within three years to enhance domestic product offerings[35] - The company aims to enhance R&D investment and innovation, introducing high-value-added products to meet the growing demand in dental healthcare and rehabilitation[183] Financial Position and Assets - The cash balance as of December 31, 2021, was approximately HKD 259.3 million, up from HKD 176.6 million in the previous year[50] - As of December 31, 2021, the equity attributable to shareholders was approximately HKD 651,100,000, an increase from HKD 636,500,000 in 2020[54] - The net current assets as of December 31, 2021, were approximately HKD 313,800,000, up from HKD 239,600,000 in 2020, with current and quick ratios of 2.20 and 2.14 respectively[54] - The company had no debt net amount as of December 31, 2021, indicating no capital debt ratio calculation[54] Operational Developments - The group generated revenue of approximately RMB 3.72 million (around HKD 4.49 million) from the first sports rehabilitation clinic, and RMB 1.66 million (around HKD 2 million) from the second clinic[28] - The group invested a total of RMB 180 million (approximately HKD 220.4 million) in limited partnership investments, focusing on information technology and quality healthcare sectors[31] - The group is actively exploring the "agriculture (culture) tourism + health" model in the Zhuhai project, which is currently under orderly construction[27] Corporate Governance - The board believes effective corporate governance is crucial for maintaining development and enhancing shareholder value[93] - The company has complied with the new corporate governance code effective from January 1, 2022, with some exceptions noted[93] - The board consists of a balanced mix of executive and independent non-executive directors, ensuring compliance with listing rules[101] - The company has established three committees: the nomination committee, remuneration committee, and audit committee, each with defined terms of reference[130] Risk Management and Compliance - The company has established multiple risk management procedures and guidelines, with the board conducting an annual review of the effectiveness of the risk management and internal control systems[146] - The internal control review indicated that significant risks threatening the achievement of business objectives have been identified and assessed[146] - The company has implemented policies for the handling and disclosure of inside information to ensure compliance with securities regulations[148] Environmental, Social, and Governance (ESG) - The ESG report aims to transparently disclose the group's performance in environmental, social, and governance aspects over the past year[172] - The company aims to integrate sustainability into its dental and health business development, recognizing the importance of ESG strategies in decision-making[181] - The company emphasizes energy conservation, greenhouse gas reduction, and providing a safe and healthy work environment for employees as part of its corporate social responsibility[185] - The company has established a comprehensive ESG framework, with various departments responsible for implementing ESG initiatives and evaluating reports[185] Employee and Stakeholder Engagement - The company conducted 67 meetings with approximately 1,067 employees during the reporting period[191] - A total of 400 interviews were held with 300 customers during the reporting period[192] - The company recognizes the importance of stakeholder communication and has set up various channels to address stakeholder feedback effectively[189]

Financial Performance - Revenue for the six months ended June 30, 2021, was HKD 103,275,000, an increase of 35.6% compared to HKD 76,175,000 for the same period in 2020[13] - Gross profit for the same period was HKD 54,058,000, representing a gross margin of 52.3%[13] - The net profit attributable to equity holders for the six months was HKD 60,666,000, compared to a loss of HKD 6,053,000 in the prior year[15] - Basic and diluted earnings per share for the period were HKD 1.20, a significant improvement from a loss of HKD 0.12 per share in the previous year[15] - Total comprehensive income for the period was HKD 65,279,000, compared to a loss of HKD 14,695,000 in the same period last year[15] - The company reported a fair value gain on financial assets of HKD 47,609,000, up from HKD 10,086,000 in the previous year[13] - The company experienced a foreign exchange gain of HKD 7,090,000, compared to a loss of HKD 8,366,000 in the previous year[15] - Total revenue for the six months ended June 30, 2021, was HKD 103,275,000, with HKD 100,441,000 from the dental business and HKD 2,834,000 from the health business[42] - The operating profit before depreciation and amortization for the dental business was HKD 15,280,000, while for the health business it was HKD 40,090,000, resulting in a total operating profit of HKD 55,370,000[42] - The total segment operating profit was HKD 42,890,000, with HKD 5,844,000 from the dental segment and HKD 37,046,000 from the health segment[42] Assets and Liabilities - Non-current assets increased to HKD 169,338,000 as of June 30, 2021, compared to HKD 425,069,000 as of December 31, 2020[17] - Current assets rose to HKD 743,546,000 as of June 30, 2021, up from HKD 332,470,000 at the end of 2020[17] - Total liabilities as of June 30, 2021, were HKD 162,661,000, with reportable segment liabilities of HKD 60,720,000 for the dental business and HKD 101,244,000 for the health business[47] - The company’s total liabilities decreased to HKD 148,110,000 as of June 30, 2021, from HKD 92,827,000 at the end of 2020[17] - The company’s inventory increased to HKD 7,951,000 as of June 30, 2021, compared to HKD 6,729,000 at the end of 2020[17] - The company’s total assets less current liabilities amounted to HKD 764,774,000 as of June 30, 2021, compared to HKD 664,712,000 at the end of 2020[17] Cash Flow - Cash and cash equivalents increased significantly to HKD 239,762,000 from HKD 176,600,000 year-over-year[23] - Net cash generated from operating activities was HKD 52,320,000 for the six months ended June 30, 2021, compared to a cash outflow of HKD 21,064,000 in the same period of 2020[23] - The company reported a net cash inflow from investing activities of HKD 8,842,000 for the first half of 2021, a recovery from a cash outflow of HKD 23,110,000 in the previous year[23] Segment Information - The company operates in two segments: manufacturing and trading of dental products and health business[38] - Revenue generated from external customers for the dental business was HKD 75,138,000 and for the health business was HKD 1,037,000, totaling HKD 76,175,000[3] - The company reported a loss before tax of HKD 6,494,000 for the health business, while the dental business generated a profit of HKD 914,000[3] Research and Development - Research and development expenses amounted to HKD 8,892,000, slightly down from HKD 9,187,000 in the previous year[54] - The company has applied for a tax deduction of 175% on research and development expenses for the taxable profits for the six months ended June 30, 2021, under a new policy effective from September 2019[59] Investments and Acquisitions - The company has entered into a cooperation agreement to invest in a subsidiary for the development of a health industry project in Zhuhai, China, with a 55% ownership stake[66] - The company plans to develop a comprehensive hospital project with 2,000 beds, focusing on organ transplantation and precision medical services[87] - The company entered into an agreement to acquire Basic Dental Implant Systems, Inc., which holds regulatory approvals and intellectual property related to dental implant systems in the U.S.[152] Shareholder Information - The company has not declared or recommended any dividends for the six months ended June 30, 2021, nor since the reporting date[60] - The issued and fully paid share capital as of June 30, 2021, was HKD 6,303,000, unchanged from December 31, 2020[115] - The total number of issued ordinary shares as of June 30, 2021, was 5,042,139,374, unchanged from December 31, 2020[186] Market and Strategic Outlook - Future outlook includes continued expansion in market presence and potential new product developments, although specific figures were not disclosed[13] - The company plans to expand its sales network both domestically and internationally, particularly in the U.S., and enhance production capacity for high-end dental products[165] - The dental market in China exceeded RMB 115 billion in 2020, with significant growth potential driven by increasing consumer spending and dental service demand[165] Miscellaneous - The company adopted revised Hong Kong Financial Reporting Standards effective January 1, 2021, which did not have a significant impact on the financial performance and position for the current and prior periods[36] - The company has not confirmed any losses from its investment in Hangzhou Jinyun for the six months ended June 30, 2021, amounting to approximately HKD 518,000[69] - The company has incurred a cumulative unrecognized loss of approximately HKD 982,000 from its investment in the associate Hangzhou Jinyun Investment Management Co., Ltd. as of June 30, 2021[69]

& Kaisa Health Group Holdings Limited 佳 兆 業 健 康 集 團 控 股 有 限 公 司 (Incorporated in Bermuda with limited liability 於百慕逵註冊成立之有限公司) (Stock Code 股份代號: 876) Annual Report 2020 年報 " ●● 000 目錄 公司資料 行政總裁報告 3 管理層討論及分析 6 董事及高層管理人員履歷 14 企業管治報告 18 環境、社會及管治報告 34 董事會報告 59 獨立核數師報告 77 綜合損益及其他全面收益表 83 綜合財務狀況表 85 綜合權益變動表 87 綜合現金流量表 88 綜合財務報表附註 90 2 財務概要 160 公司資料 董事 執行董事 2 佳兆業健康集團控股有限公司 年報2020 張華綱先生（主席） 羅軍先生（聯席副主席兼行政總裁） 武天逾先生（聯席副主席） 郭英成先生 獨立非執行董事 劉彥文博士 呂愛平博士 李永蘭女士 審核委員會 劉彥文博士（主席） 呂愛平博士 李永蘭女士 薪酬委員會 呂愛平博士（主席） 武天逾先生 劉彥文博士 提名委員會 張華 ...

Financial Performance - Revenue for the six months ended June 30, 2020, was HKD 76,175,000, a decrease of 36% compared to HKD 118,818,000 for the same period in 2019[13] - Gross profit for the period was HKD 36,916,000, down from HKD 58,693,000 in the previous year, reflecting a decline in gross margin[13] - The company reported a loss of HKD 6,329,000 for the six months ended June 30, 2020, compared to a profit of HKD 5,311,000 in the same period of 2019[13] - Total comprehensive loss for the period was HKD 14,695,000, compared to a total comprehensive income of HKD 1,826,000 in the same period last year[13] - Basic and diluted loss per share was HKD (0.12) for the current period, compared to earnings of HKD 0.11 per share in the previous year[13] - The company reported a pre-tax loss of HKD 6,494,000 for the six months ended June 30, 2020, compared to a profit of HKD 5,005,000 in the same period of 2019[42] - The loss attributable to equity holders of the company was approximately HKD 6.1 million, compared to a profit of HKD 5.4 million in the same period of 2019[157] Expenses and Costs - The company experienced a significant increase in selling and distribution costs, which amounted to HKD 12,767,000, compared to HKD 22,598,000 in the previous year[13] - Administrative expenses increased to HKD 38,481,000 from HKD 34,247,000 year-on-year, indicating rising operational costs[13] - The company incurred research and development expenses of HKD 9,187,000, a decrease of 35.3% from HKD 14,292,000 in the previous year[76] - The company recognized a finance cost of HKD 283,000 related to lease liabilities, an increase from HKD 143,000 in the previous year[75] Assets and Liabilities - As of June 30, 2020, total assets amounted to HKD 1,030,473 thousand, a decrease from HKD 1,014,857 thousand as of December 31, 2019, reflecting a growth of approximately 1.5%[14] - Current liabilities rose to HKD 76,894 thousand, up from HKD 67,886 thousand, indicating an increase of approximately 13.5%[14] - The company’s total liabilities increased to HKD 391,824 thousand from HKD 373,196 thousand, reflecting a rise of approximately 5.0%[14] - The total equity attributable to equity holders of the company decreased to HKD 628,228 thousand from HKD 642,007 thousand, a reduction of about 2.1%[15] - The company’s reserves decreased to HKD 621,925 thousand from HKD 635,704 thousand, a decline of about 2.2%[15] Cash Flow - The net cash used in operating activities for the six months ended June 30, 2020, was HKD (42,636) thousand, compared to HKD (128,521) thousand for the same period in 2019, showing an improvement of about 66.8%[20] - Cash and cash equivalents decreased to HKD 181,655 thousand from HKD 230,176 thousand, a decline of approximately 21.1%[20] - The company reported a net cash outflow from investing activities of HKD (23,344) thousand, a significant decrease from HKD 100,920 thousand in the previous year[20] Market and Business Strategy - The company is focusing on improving operational efficiency and exploring new market opportunities to enhance future performance[13] - The company is focusing on expanding its operations in the dental and health sectors, with ongoing assessments of market conditions and potential strategic initiatives[68] - The company aims to enhance shareholder value by expanding its denture business and integrating high-quality medical device resources domestically and internationally[171] - The company plans to establish a comprehensive hospital with 2,000 beds in Hangzhou, enhancing its health investment portfolio and market reputation in China[175] Compliance and Governance - The financial statements for the six months ended June 30, 2020, were prepared in accordance with Hong Kong Accounting Standards and applicable disclosure requirements[21] - The company confirmed compliance with the corporate governance code during the six months ended June 30, 2020[200] Shareholder Information - The board did not recommend the payment of an interim dividend for the period[158] - The total number of issued ordinary shares remained at 5,042,139,374 as of June 30, 2020, unchanged from December 31, 2019[192] - The company has adopted a share option scheme as a long-term incentive for directors and eligible employees[194]

Financial Performance - The company recorded revenue of approximately HKD 251.6 million for the year ended December 31, 2019, representing a 4% increase from HKD 241.9 million in 2018[6]. - The loss attributable to shareholders was HKD 354.7 million, compared to a loss of HKD 22 million in 2018, with a loss per share of HKD 0.0703[6]. - The group's revenue for the year reached approximately HKD 251.6 million, an increase of 4% compared to HKD 241.9 million in the previous year[21]. - The group reported a loss attributable to shareholders of approximately HKD 354.7 million, with a basic loss per share of HKD 0.0703, compared to a loss of HKD 22 million and a basic loss per share of HKD 0.0043 in the previous year[21]. - Revenue from the denture business was approximately HKD 251.2 million, compared to HKD 241.9 million in the same period last year[23]. - Domestic sales accounted for 65% of total sales in 2019, up from 48% in 2018, while overseas sales dropped to 35% from 52%[25]. - The growth rate of the denture business was significantly reduced from an estimated 35.5% in 2018 to approximately 6.7% due to the impact of the US-China trade war and COVID-19[28]. - The gross profit for the year was HKD 122.9 million, with a gross profit margin of 48.8%, up from 45.3% in the previous year[41]. Business Development - The dental business continues to grow steadily, with a significant sales and service network established across over 20 countries, including the US and Europe[7]. - Despite a decrease in export orders due to the US-China trade war, domestic sales in China increased significantly, contributing to the overall revenue growth[8]. - The company plans to expand its dental business by increasing production capacity in China and developing high-end dental products with cosmetic functions[12]. - The newly launched transparent aligners have shown strong performance in driving revenue growth[13]. - The company is actively seeking investment opportunities in the global dental equipment market to enhance shareholder value[15]. - The rehabilitation center in Shenzhen aims to provide professional services through a chain store model, expected to contribute positively to revenue growth[16]. - The group has established a rehabilitation center in Shenzhen, which is expected to significantly drive revenue growth[39]. - The group plans to build a comprehensive hospital with 2,000 beds as part of the Hangzhou Shulan project, enhancing its health investment portfolio[38]. - The group aims to expand its dental business both domestically and internationally, including the U.S. market, to enhance shareholder value[36]. - The group has set a series of growth strategies for its dental business, including expanding production capacity in China[36]. Research and Development - Research and development expenditure increased to HKD 32.6 million from HKD 26.5 million in the previous year, reflecting the management's commitment to investing in future technologies[27]. - The group has increased its R&D spending to improve future product competitiveness, including investments in 3D printing technology[45]. Financial Position - Cash and cash equivalents as of December 31, 2019, were approximately HKD 230.2 million, up from HKD 194.8 million in 2018[50]. - As of December 31, 2019, the equity attributable to shareholders was approximately HKD 642 million, a decrease from HKD 1,005 million as of December 31, 2018, representing a decline of about 36%[56]. - The group's net current assets as of December 31, 2019, were approximately HKD 344.7 million, down from HKD 449 million as of December 31, 2018, indicating a decrease of around 23%[56]. - The current and quick ratios as of December 31, 2019, were 6.08 and 5.98, respectively, compared to 8.20 and 8.09 as of December 31, 2018, showing a decline in liquidity ratios[56]. - The group had no bank borrowings or long-term debts as of December 31, 2019, resulting in no capital debt ratio calculation[57]. Corporate Governance - The company emphasizes effective corporate governance as a key factor for maintaining development and enhancing shareholder value[86]. - The board of directors is responsible for the overall management of the company's business and aims to enhance shareholder value through guidance and supervision[88]. - The company has complied with the corporate governance code, except for specific deviations noted in the report[86]. - The company regularly reviews its corporate governance practices to ensure compliance with legal and regulatory standards[87]. - The company has a strong management team with diverse backgrounds in finance and operations, enhancing its strategic capabilities[81]. - The company has established a network of clients both in China and overseas, demonstrating its marketing and management expertise[78]. - The board of directors includes four executive directors and five independent non-executive directors, ensuring compliance with listing rules regarding independence[90][91]. - The company has adopted a board diversity policy, considering factors such as gender, age, and professional experience in director nominations[99]. - The company has established a remuneration committee to review the remuneration policies for directors and senior management, ensuring transparency and adherence to market practices[123]. Risk Management - The company engaged an independent international auditing firm to conduct risk assessments and review internal control systems[136]. - Key risks identified include strategic, operational, information, and financial risks, which were qualitatively and quantitatively assessed[136]. - The internal audit plan was adopted based on the risk assessment results and will be updated annually to reflect existing risks[136]. - The board confirmed that the risk management and internal control systems were effective and sufficient during the year[137]. Environmental, Social, and Governance (ESG) - Kaisa Health Group reported a significant focus on environmental, social, and governance (ESG) performance for the year ending December 31, 2019[159]. - The board of directors is responsible for the overall strategy and reporting of the group's ESG initiatives, ensuring sustainable development through green operations[160]. - The report highlights the environmental impact of Kaisa Health's operations in Shenzhen, particularly in the manufacturing and trading of dental prosthetics[161]. - Kaisa Health is committed to promoting sustainable development and social responsibility through its ESG practices[159]. - The company generated a total of 2,197.81 tons of CO2 equivalent emissions during the reporting period[181]. - The company produced 86 tons of non-hazardous waste during the reporting period[185]. - The total energy consumption was 2,557,920 kWh, and water consumption was 24,197 cubic meters during the reporting period[186]. - The company has established various communication channels to effectively address stakeholder concerns and feedback[167]. Employee Management - The company has a total of 1,263 employees, with 592 male and 671 female employees as of December 31, 2019[195]. - The company conducted 75 training sessions during the reporting period, totaling 11,343 training hours, with an average of 2.44 hours per employee[199]. - The company has implemented strict employee management policies to regulate dismissal procedures, ensuring compliance with labor laws[194]. - The company has a policy against child labor and forced labor, ensuring compliance with relevant laws and regulations[200]. - The company has a commitment to employee health, providing pre-employment medical examinations for all new hires[198].

Financial Performance - Revenue for the six months ended June 30, 2019, was HKD 118,818,000, a decrease of 6.5% from HKD 127,126,000 in the same period of 2018[14] - Gross profit for the same period was HKD 58,693,000, down from HKD 61,078,000, reflecting a decline of 3.9%[14] - The net profit for the period was HKD 5,311,000, significantly up from HKD 1,105,000 in the previous year, representing an increase of 380.3%[14] - Basic and diluted earnings per share were both HKD 0.11, compared to HKD 0.02 in the prior year, marking a 450% increase[14] - Other income and gains increased to HKD 12,182,000 from HKD 4,998,000, a rise of 143.5%[14] - The overall operating profit for the group was HKD 9,058,000, with the dental business contributing HKD 18,209,000 and the health business reporting a loss of HKD 9,151,000[77] - The group incurred a total of HKD 9,269,000 in undistributed expenses, leading to a profit before tax of HKD 5,005,000[76] - The company reported a pre-tax profit of HKD 4,266,000, demonstrating a recovery from previous losses[81] - Profit attributable to equity holders was approximately HKD 5.4 million, up from HKD 1.1 million in the same period of 2018[171] Cash Flow and Assets - The company's net cash used in operating activities for the six months ended June 30, 2019, was HKD (128,521,000), compared to HKD (18,079,000) for the same period in 2018, indicating a significant increase in cash outflow[22] - The company reported a net cash inflow from investing activities of HKD 100,920,000 for the six months ended June 30, 2019, compared to a net cash outflow of HKD (116,304,000) in the same period of the previous year[22] - As of June 30, 2019, total assets amounted to HKD 1,023,259,000, an increase from HKD 1,012,034,000 as of December 31, 2018, reflecting a growth of approximately 1.2%[15] - The company’s total liabilities decreased to HKD 13,458,000 as of June 30, 2019, from HKD 6,940,000 at the end of 2018, indicating a significant increase in liabilities[15] - The company’s inventory and trade receivables totaled HKD 93,671,000 as of June 30, 2019, compared to HKD 78,528,000 at the end of 2018, marking an increase of approximately 19.2%[15] - The cash and cash equivalents decreased to HKD 163,689,000 as of June 30, 2019, from HKD 438,994,000 at the end of 2018, a decline of about 62.7%[22] Segment Performance - Total revenue for the six months ended June 30, 2019, was HKD 118,818,000, solely from the dental business[77] - The dental business reported a segment profit before depreciation and amortization of HKD 23,966,000, while the health business incurred a loss of HKD 8,075,000, resulting in a total segment profit of HKD 15,891,000[77] - The health business segment was introduced in the financial reporting starting from the six months ended June 30, 2018[73] - The group has not reported any revenue from the health business segment for the six months ended June 30, 2019[77] Research and Development - Research and development expenses for the period were HKD 14,292,000, an increase from HKD 10,453,000 in the previous year, highlighting the company's commitment to innovation[95] - The group launched an upgraded version of its dental veneer product, XS, which addresses severe discoloration issues and has been globally released[180] Strategic Initiatives - The company aims to expand its market presence and enhance product offerings in the upcoming quarters[14] - Future guidance indicates a focus on improving operational efficiency and exploring strategic partnerships for growth[14] - The company aims to enhance shareholder value by expanding its denture business and integrating high-quality medical device resources[178] - The company plans to establish a medical service system that combines healthcare and rehabilitation, creating a synergistic ecosystem[178] - The group plans to establish a comprehensive hospital with 2,000 beds in Hangzhou, enhancing its health investment portfolio and market reputation in China[181] Financial Reporting and Compliance - The group has adopted HKFRS 16 "Leases" effective January 1, 2019, impacting the measurement and recognition of lease liabilities and right-of-use assets[63] - The new HKFRS 16 replaced HKAS 17 and was applied using a modified retrospective approach without restating prior periods[38] - The adoption of new and revised HKFRS did not have a significant impact on the financial performance and position for the current and prior periods[37] Shareholder Information - The company did not declare or recommend any dividends for the six months ended June 30, 2019, nor for the same period in 2018[101] - The number of issued and fully paid ordinary shares as of June 30, 2019, was 5,042,139,374, a decrease from 5,101,609,374 as of January 1, 2018, due to share buybacks[147] - The company recognized share-based payment expenses of HKD 2,881,000 for the six months ended June 30, 2019, compared to HKD 6,493,000 for the same period in 2018[153]

Financial Performance - The company reported revenue of approximately HKD 241.9 million for the year ended December 31, 2018, representing a 7% increase from HKD 226.7 million in 2017[9]. - The company incurred a loss attributable to shareholders of HKD 22 million, compared to a profit of HKD 3.9 million in 2017, resulting in a loss per share of HKD 0.43[9]. - The group's revenue from continuing operations for the year reached approximately HKD 241.9 million, an increase of 7% compared to HKD 226.7 million in 2017[20]. - The group reported a loss attributable to shareholders of approximately HKD 22 million, translating to a basic loss per share of HKD 0.43, compared to a profit of HKD 3.9 million and a basic earnings per share of HKD 0.10 in 2017[20]. - Gross profit from continuing operations for the year was HKD 109.7 million, down from HKD 113.5 million in 2017, with a gross margin of 45.3% compared to 50.0% in 2017[35]. Business Growth and Strategy - The dental business has shown steady growth since its acquisition in May 2015, with a significant sales and service network established across over 20 countries[10]. - Despite a decrease in export orders due to the US-China trade war, domestic sales in China increased significantly, contributing to overall revenue growth[11]. - The company plans to expand its sales network both domestically and internationally, particularly in the US, and increase production capacity in China[13]. - The acquisition of Hangzhou Shulan Hospital project is expected to enhance the company's presence in the healthcare sector, with plans to build a 2,000-bed hospital[11]. - The company aims to explore investment opportunities in the healthcare sector, including partnerships and investments in hospitals and elderly care industries[13]. - The management anticipates significant growth potential in the dental technology market, driven by improvements in living standards and the overall development of the healthcare industry in China[15]. - The group’s denture business generated revenue of approximately HKD 241.9 million, showing steady growth despite pressures from the US-China trade war[22]. - The company aims to expand its sales network in both domestic and overseas markets, including the United States, and to develop high-end new denture products[31]. - The Chinese dental market is expected to maintain rapid growth, driven by rising consumer spending and increased awareness of oral health[28]. Research and Development - The company is focusing on increasing R&D investment and introducing high-value products to meet the growing demand for dental products[15]. - Research and development expenditure increased to HKD 26.5 million from HKD 16.1 million in 2017, reflecting the management's commitment to investing in future technologies[25]. - R&D expenses increased as the group intensified its investment in R&D to enhance future product competitiveness, including projects like 3D carving machines and 3D printing technology[40]. Management and Governance - 罗军先生 appointed as CEO and Executive Director since February 26, 2019, previously served as Chairman of the Board[60]. - Wu Tianyu served as CEO from May 21, 2015, until February 26, 2019, and has over 30 years of experience in the dental industry[61]. - Xu Hao appointed as Executive Director effective February 28, 2019, and has over 12 years of experience in offshore financing and capital markets[66]. - The company has a strong management team with diverse backgrounds in finance, healthcare, and operations, enhancing its strategic capabilities[74]. - The company is focused on expanding its market presence and enhancing operational efficiency through strategic leadership[74]. - The board includes members with significant experience in corporate governance and strategic management, ensuring effective oversight[70]. - The company is committed to developing new products and technologies to meet market demands and enhance competitiveness[74]. Corporate Governance - The Board of Directors emphasizes effective corporate governance as a key factor for maintaining development and enhancing shareholder value[80]. - The company has complied with the corporate governance code, with the exception of specific provisions, ensuring adherence to legal and regulatory standards[80]. - The Board consists of a balanced mix of executive and independent non-executive directors, meeting the requirement of at least one independent director with appropriate professional qualifications[85]. - The Chairman, Guo Yingcheng, is responsible for setting the overall corporate development direction and ensuring good governance practices are established and executed[88]. - The CEO, Luo Jun, manages the daily operations and implements approved strategies[89]. - The Nomination Committee has been established to review the appointment of new directors and related matters, ensuring a structured approach to governance[91]. - The board of directors had a total of 12 meetings in the fiscal year to review and approve financial and operational performance[105]. Risk Management and Internal Control - The company engaged an independent international auditing firm to conduct risk assessment and review internal control systems, identifying key risks including strategic, operational, information, and financial risks[135]. - The board confirmed that the risk management and internal control systems are effective and sufficient, with significant risks identified and assessed during the year[136]. - The company will update its risk assessment and internal audit plan annually to reflect existing risks[135]. - The board is responsible for the management of risks and internal control systems, which are designed to manage rather than eliminate risks that could impede business objectives[135]. Environmental Responsibility - The company reported a significant focus on environmental responsibility, aiming to reduce carbon emissions and wastewater discharge as part of its operational impact management[173]. - The company has established management guidelines to minimize environmental impact, including regulations on vehicle use, wastewater management, and solid waste management[173]. - The total greenhouse gas emissions amounted to 2,265,847 kg CO2 equivalent during the reporting period[175]. - The company has implemented measures to reduce energy consumption, including the purchase of energy-efficient products and promoting paperless operations[184]. Employee Health and Safety - The company emphasizes the importance of employee health and safety, regularly conducting safety training and fire drills[195]. - The company has established a medical examination system for employees, providing pre-employment medical checks to ensure fitness for work[196]. - The company has implemented a dust filtration system in production workshops and provided personal protective equipment to ensure employee health[196]. - There were 10 reported workplace injury cases during the reporting period, resulting in a loss of 130 workdays due to occupational diseases and injuries[195].